Development PipelineTucatinib

a highly selective small molecule tyrosine kinase inhibitor being investigated in multiple HER2-overexpressed/amplified and HER2-mutated cancers

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Clinical Trials

CompassHER2 RD: HER2+ breast cancer

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-02: HER2+ breast cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-05: HER2+ breast cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

MOUNTAINEER-03: HER2+ colorectal cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

HER2CLIMB-04: HER2+ breast cancer

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNTUC-019: Locally advanced or metastatic solid tumors with HER2 alterations

ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

SGNTUC-024: HER2+ gastrointestinal cancers

ClinicalTrials.Seagen.com ClinicalTrials.gov

Phase 1
Phase 2
Phase 3

Program Resources

High-level synopsis of tucatinib and ongoing clinical trials

View/Download

Detailed information about tucatinib clinical trials

View in Interactive Pipeline